Company Name, Ticker, Industry, else..

Gw Pharmaceuticals Plc (NASDAQ: GWPH)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Gw Pharmaceuticals Plc's

Name: Gw Pharmaceuticals Plc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

GWPH Sales vs. its Competitors Q1 2021

Comparing the current results to its competitors, Gw Pharmaceuticals Plc reported Revenue increase in the 1 quarter 2021 by 26.39 % year on year.
The sales growth was above Gw Pharmaceuticals Plc's competitors' average revenue growth of 1.49 %, achieved in the same quarter.

• List of GWPH Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Gw Pharmaceuticals Plc, faster than the decline experienced by the competitors recorded a net loss, as well as most of its competitors.

<< GWPH Stock Performance Comparisons

<< See the full list of GWPH competitors

Overall company Market Share Q1 2021

Due to strong revenue growth of 26.39 % in Overall company company increased its market share in this division. << More on GWPH Market Share.

*Market share is calculated based on total revenue.

GWPH's Stock Performance relative to its Competitors

Publicly Traded Peers of Gw Pharmaceuticals Plc

Anebulo Pharmaceuticals Inc
Share Performance

-87.20%

One Year

Anebulo Pharmaceuticals Inc

Profile

Anebulo Pharmaceuticals Inc operates on a business model focused on developing and commercializing innovative therapeutic solutions for respiratory diseases. They aim to identify and target unmet medical needs through research and development of novel drug formulations and delivery systems. By partnering with stakeholders and leveraging their expertise, Anebulo Pharmaceuticals Inc aims to provide effective treatments and improve the lives of patients with respiratory conditions.

More about Anebulo Pharmaceuticals Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 13.147 mill.	$ - mill.	$ -7.979 mill.

Tvardi Therapeutics Inc
Share Performance

-93.91%

One Year

Tvardi Therapeutics Inc

Profile

The company develops oral small molecule inhibitors targeting STAT3 for the treatment of inflammatory and proliferative diseases.

More about Tvardi Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 17.402 mill.	$ - mill.	$ -30.736 mill.

Skye Bioscience Inc
Share Performance

+147.91%

This Quarter

Skye Bioscience Inc

Profile

Skye Bioscience Inc operates under a business model focused on developing and commercializing innovative therapeutic treatments. The company primarily engages in research and development activities to discover novel drugs targeting specific medical conditions and diseases. Skye Bioscience Inc aims to generate revenue by successfully bringing these drugs to market through partnerships, licensing agreements, or direct sales.

More about Skye Bioscience Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 8.780 mill.	$ - mill.	$ -57.331 mill.

Promis Neurosciences inc
Share Performance

+21.77%

One Year

Promis Neurosciences inc

Profile

Promis Neurosciences Inc is a biotech company focused on developing innovative therapies for neurodegenerative diseases like Alzheimer's and ALS. Their business model revolves around leveraging their expertise in neurosciences to discover and develop novel drug candidates that target protein misfolding, a key driver of these diseases. By translating their research into potential therapies, Promis Neurosciences aims to address unmet medical needs and improve the lives of patients suffering from neurodegenerative disorders.

More about Promis Neurosciences inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 119.674 mill.	$ - mill.	$ -42.228 mill.

Nu med Plus Inc
Share Performance

+61.97%

This Year

Nu med Plus Inc

Profile

Nu med Plus Inc operates as a medical device development and manufacturing company, specializing in the production of innovative nitric oxide (NO) delivery systems for use in various medical applications. The company primarily generates revenue by designing, manufacturing, and selling its NO delivery systems to healthcare providers, enabling them to improve patient outcomes and facilitate advanced therapeutic treatments.

More about Nu med Plus Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 1.922 mill.	$ - mill.	$ -0.008 mill.

13 more competitors available

Sources: Gw Pharmaceuticals Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Thursday, September 3, 2026 11:41 AM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Gw Pharmaceuticals Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.